UCB SA (0NZT) Price & Analysis

0NZT Stock Chart & Stats

€281.25€1.25(0.45%)

At close: Oct 30 4:00 PM EDT

Day’s Range: EUR 275.80 - EUR 283.10
52-Week Range: EUR 197.45 - EUR 289.50
Previous Close: EUR 280.00
Volume: 20.59K
Average Volume (3M): 54.52K
Market Cap: EUR 53.46B
Enterprise Value: EUR 53.61B
Total Cash (Recent Filing): EUR 1.76B
Total Debt (Recent Filing): EUR 3.03B
Price to Earnings (P/E): 24.4
Beta: 0.80
Next Earnings: Feb 25, 2027
EPS Estimate: 7.08
Next Dividend Ex-Date: N/A
Dividend Yield: 0.51%

UCB SA News

Stacy Ku Initiates Buy on UCB, Citing Attractive Valuation and Early Bimzelx-Driven Growth Inflection

TD Cowen analyst Stacy Ku maintained a Buy rating on UCB SA on July 30 and set a price target of $165.00. Stacy Ku has given his Buy rating due

3M agoUNC UCBJF

UCB upgraded to Hold from Underperform at Jefferies

Jefferies upgraded UCB (UCBJF) to Hold from Underperform with a price target of EUR 220, up from EUR 212. The firm says its sell thesis has played out while UCB’s

3M agoUNC UCBJF

Hold Rating Maintained as De-Rated Valuation Balances Risk-Reward; Price Target Raised from $212 to $220 on Improved EBITDA Outlook Amid Ongoing Bimzelx Concerns

In a report released today, Michael Leuchten from Jefferies upgraded UCB SA to a Hold, with a price target of €220.00. Michael Leuchten has given his Hold rating due to

3M agoUNC UCBJF

UCB price target raised to EUR 305 from EUR 290 at Berenberg

Berenberg analyst Kerry Holford raised the firm’s price target on UCB (UCBJF) to EUR 305 from EUR 290 and keeps a Buy rating on the shares. Published first on TheFly

4M agoUNC UCBJF

UCB downgraded to Equal Weight from Overweight at Barclays

Barclays analyst Charles Pitman-King downgraded UCB (UCBJF) to Equal Weight from Overweight with a price target of EUR 300, down from EUR 310. The firm cites the company’s growth investments

4M agoUNC UCBJF

Cullinan jumps after UCB acquires Candid Therapeutics

Shares of Cullinan Therapeutics (CGEM) are moving higher after UCB (UCBJF) announced an agreement to acquire privately held Candid Therapeutics. Cizutamig, Candid’s lead investigational asset, is “positioned as a potential

6M agoCGEM UNC

UCB to acquire Neurona Therapeutics

UCB (UCBJF) announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Therapeutics is

6M agoUNC UCBJF

UCB downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley analyst Sarita Kapila downgraded UCB (UCBJF) to Equal Weight from Overweight with an unchanged price target of EUR 260. The firm sees a balanced risk/reward at current share

8M agoUNC UCBJF

UCB initiated with an Outperform at Wolfe Research

Wolfe Research analyst Rudy Li initiated coverage of UCB (UCBJF) with an Outperform rating and EUR 340 price target The firm launched coverage of the neuroscience biotech sector with a

8M agoUNC UCBJF

UCB price target raised to EUR 304 from EUR 255 at Goldman Sachs

Goldman Sachs raised the firm’s price target on UCB (UCBJF) to EUR 304 from EUR 255 and keeps a Buy rating on the shares. Published first on TheFly – the

8M agoUNC UCBJF

UCB price target raised to EUR 310 from EUR 270 at Barclays

Barclays raised the firm’s price target on UCB (UCBJF) to EUR 310 from EUR 270 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate

9M agoUNC UCBJF

UCB price target raised to EUR 295 from EUR 285 at Deutsche Bank

Deutsche Bank raised the firm’s price target on UCB (UCBJF) to EUR 295 from EUR 285 and keeps a Buy rating on the shares. Published first on TheFly – the

10M agoUNC UCBJF

UCB SA’s Growth Potential: Buy Rating on Bimzelx’s Transformative Impact

Goldman Sachs analyst Rajan Sharma has maintained their bullish stance on 0NZT stock, giving a Buy rating on July 14. Rajan Sharma has given his Buy rating due to a

1y agoUNC UCBJF

0NZT FAQ

What was UCB SA’s price range in the past 12 months?

UCB SA lowest share price was €197.45 and its highest was €289.50 in the past 12 months.

What is UCB SA’s market cap?

UCB SA’s market cap is €53.46B.

When is UCB SA’s upcoming earnings report date?

UCB SA’s upcoming earnings report date is Feb 25, 2027 which is in 116 days.

How were UCB SA’s earnings last quarter?

UCB SA released its earnings results on Jul 30, 2026. The company reported €6.84 earnings per share for the quarter, beating the consensus estimate of €5.085 by €1.755.

Is UCB SA overvalued?

According to Wall Street analysts UCB SA’s price is currently Undervalued.

Does UCB SA pay dividends?

UCB SA does not currently pay dividends.

What is UCB SA’s EPS estimate?

UCB SA’s EPS estimate is 7.08.

How many shares outstanding does UCB SA have?

UCB SA has 194,505,660 shares outstanding.

What happened to UCB SA’s price movement after its last earnings report?

UCB SA reported an EPS of €6.84 in its last earnings report, beating expectations of €5.085. Following the earnings report the stock price went down -12.559%.

Which hedge fund is a major shareholder of UCB SA?

Currently, no hedge funds are holding shares in GB:0NZT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

UCB SA

UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.

UCB SA (0NZT) Earnings & Revenues

Historic Earnings Reports

0NZT Stock 12 Month Forecast

Average Price Target

EUR 291.00▲(3.47% Upside)

Past 12 Months12 Month ForecastJan2026Oct2026

HighEUR 340.00

AverageEUR 291.00

LowEUR 250.00

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	15	1	6
Technical Analysis	3	1	6
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to GB:0NZT
Company	Price & Change	Follow
GB:AZNAstraZeneca
GB:GSKGlaxoSmithKline
GB:HIKHikma Pharmaceuticals

Compare GB:0NZT Stocks >

Ownership Overview

13.18% Mutual Funds
<0.01% Other Institutional Investors
76.44% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

UCB SA stock analysis

UCB SA (0NZT) Price & Analysis

0NZT Stock Chart & Stats

UCB SA News

Stacy Ku Initiates Buy on UCB, Citing Attractive Valuation and Early Bimzelx-Driven Growth Inflection

UCB upgraded to Hold from Underperform at Jefferies

Hold Rating Maintained as De-Rated Valuation Balances Risk-Reward; Price Target Raised from $212 to $220 on Improved EBITDA Outlook Amid Ongoing Bimzelx Concerns

UCB price target raised to EUR 305 from EUR 290 at Berenberg

UCB downgraded to Equal Weight from Overweight at Barclays

Cullinan jumps after UCB acquires Candid Therapeutics

UCB to acquire Neurona Therapeutics

UCB downgraded to Equal Weight from Overweight at Morgan Stanley

UCB initiated with an Outperform at Wolfe Research

UCB price target raised to EUR 304 from EUR 255 at Goldman Sachs

UCB price target raised to EUR 310 from EUR 270 at Barclays

UCB price target raised to EUR 295 from EUR 285 at Deutsche Bank

UCB SA’s Growth Potential: Buy Rating on Bimzelx’s Transformative Impact

0NZT FAQ

Company Description

UCB SA

UCB SA (0NZT) Earnings & Revenues

0NZT Stock 12 Month Forecast

Average Price Target

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium